Latest news in cancer
Childhood leukemia and its treatment
Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute...
CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma
March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white...
High Intensity Focused Ultrasound
March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts...
CAR-T Cell therapy could be made safer and more widely available with a few adjustments
March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment’s remarkable...
CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment cost, latest CAR-T clinical trial recruitment
March 2022: CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment price, cost, the latest CAR-T clinical trial recruitment...
Olaparib is approved for adjuvant treatment of high-risk early breast cancer
March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients...
Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy...
Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma
March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal...
Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma
March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug...
Abatacept is approved for prophylaxis of acute graft versus host disease
March 2022: Abatacept (Orencia, Bristol-Myers Squibb Company) has been approved by the Food and Drug Administration for the prevention of acute graft versus...
Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma
March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR...
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.